MedTrace Logo

Injection Management With Betaferon: Influence on Adherence, Patients Satisfaction and Health Related Outcomes (BETAPATH)

NCT00902135 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 702

Last updated 2015-07-17

No results posted yet for this study

Summary

Aim of the BETAPATH study is to evaluate whether the use of a personal digital assistant (PDA) can improve the adherence of Multiple Sclerosis patients to a therapy with Betaseron. The Personal digital assistant PDA functions as an electronic diary and as an injection reminder.

Conditions

  • Relapsing-Remitting Multiple Sclerosis

Interventions

DRUG

Interferon beta-1b (Betaseron, BAY86-5046)

Interferon beta-1b (Betaferon) and Personal Digital Assistant together with a reminder

DRUG

Interferon beta-1b (Betaseron, BAY86-5046)

Interferon beta-1b (Betaferon) and Personal Digital Assistant without a reminder

DRUG

Interferon beta-1b (Betaseron, BAY86-5046)

Interferon beta-1b (Betaferon)

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-05-31
Primary Completion
2013-12-31
Completion
2014-08-31

Countries

  • Germany

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00902135 on ClinicalTrials.gov